RGEN
NASDAQRepligen Corporation
Website
News25/Ratings12
Price$114.13-49.31 (-30.17%)
2026-01-202026-04-23
News · 26 weeks45-50%
2025-10-262026-04-19
Mix2790d
- Insider13(48%)
- Other5(19%)
- SEC Filings5(19%)
- Earnings3(11%)
- Analyst1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Loeillot Olivier4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen to Report First Quarter 2026 Financial ResultsWALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. The w
- SECSEC Form 144 filed by Repligen Corporation144 - REPLIGEN CORP (0000730272) (Subject)
- ANALYSTRothschild & Co Redburn initiated coverage on Repligen with a new price targetRothschild & Co Redburn initiated coverage of Repligen with a rating of Buy and set a new price target of $160.00
- PRRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support NetworkWALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center ("RTIC") at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen's innovative bioprocessing solutions. The Breda RTIC is Repligen's third global training and innovation center, joining existing locations in Waltham,
- SECSEC Form DEFA14A filed by Repligen CorporationDEFA14A - REPLIGEN CORP (0000730272) (Filer)
- SECSEC Form DEF 14A filed by Repligen CorporationDEF 14A - REPLIGEN CORP (0000730272) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Repligen CorporationSCHEDULE 13G/A - REPLIGEN CORP (0000730272) (Subject)
- INSIDERSEC Form 4 filed by Kuriyel Ralf4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Loeillot Olivier4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Bylund James4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSEC Form 4 filed by Garland Jason K4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERChief Operating Officer Bylund James was granted 125 shares and covered exercise/tax liability with 62 shares, increasing direct ownership by 0.36% to 17,672 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSenior VP, R&D Kuriyel Ralf was granted 125 shares and covered exercise/tax liability with 42 shares, increasing direct ownership by 0.56% to 14,778 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen Corporation to Present at Upcoming March ConferencesWALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three upcoming investor conferences. The Leerink Global Healthcare Conference, being held March 8 – 11 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 11:20 a.m. ET on Tuesday, March 10, 2026.The Barclays 28th Annual Global Healthcare Conference, being held March 10 – 12 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 10:30 a.m. ET on Wednesday, March 11, 2026.The 2026 KeyBanc Virtual
- INSIDERChief Operating Officer Bylund James covered exercise/tax liability with 3,911 shares, decreasing direct ownership by 18% to 17,609 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERChief Executive Officer Loeillot Olivier covered exercise/tax liability with 1,954 shares, decreasing direct ownership by 5% to 33,944 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Hunt Anthony covered exercise/tax liability with 9,897 shares, decreasing direct ownership by 10% to 89,062 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERCFO Garland Jason K covered exercise/tax liability with 1,042 shares, decreasing direct ownership by 8% to 12,341 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERSenior VP, R&D Kuriyel Ralf covered exercise/tax liability with 1,367 shares, decreasing direct ownership by 9% to 14,695 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERCHIEF PRODUCT OFFICER Douglass Brian Robb covered exercise/tax liability with 221 shares, decreasing direct ownership by 3% to 8,319 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- SECSEC Form 10-K filed by Repligen Corporation10-K - REPLIGEN CORP (0000730272) (Filer)
- SECRepligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REPLIGEN CORP (0000730272) (Filer)
- PRRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial GuidanceFourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve-
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Repligen CorporationSCHEDULE 13G/A - REPLIGEN CORP (0000730272) (Subject)